Stockscreener 앱 받기
60.76
0.28%
-0.17
시간 외 거래:
61.15
0.39
+0.64%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal - plansponsor
DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief - Law360
Bristol Myers Squibb stock stabilizes as Eliquis and Opdivo help offset Revlimid erosion - Ad-hoc-news.de
Donald TrumpBRISTOL MYERS SQUIBB CO Trump Trade on May. 18, 2026 - Quiver Quantitative
Bristol Myers Squibb stock steadies as Eliquis and Opdivo shape earnings outlook - Ad-hoc-news.de
Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued? - simplywall.st
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Alexandria Real Estate Equities (ARE) Delivers 427,000 RSF Bristol Myers Squibb R And D Hub - Yahoo Finance
Bristol Myers Squibb stock edges higher as recent results and oncology portfolio shape investor view - Ad-hoc-news.de
Bristol Myers Squibb Partners With NVIDIA to Build Pharma's Largest Supercomputer - Mjengo Hub
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Sahm
Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery - Yahoo Finance UK
Bristol Myers Squibb stock trades steadily as oncology and immunology portfolio supports earnings tr - Ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as oncology pipeline and recent earnings shape sentiment - Ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as oncology pipeline and Revlimid erosion shape outlook - Ad-hoc-news.de
BMS: Boosting AI Drug Discovery Capacity with NVIDIA Tech - Healthcare Digital
Bristol Myers Squibb Expands AI Infrastructure With NVIDIA to Build AI Factory for Drug Discovery - Digital Health News
Bristol Myers Squibb buys Nvidia AI system for drug discovery - AI News
Bristol Myers Squibb stock trades steady as oncology pipeline and recent results frame investor focu - Ad-hoc-news.de
Bristol Myers Squibb (BMY) Expands AI Capabilities with Nvidia S - GuruFocus
BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's. - drugdiscoverytrends.com
Bristol Myers Squibb (BMY) Enhances AI Capabilities with New NVI - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Bristol Myers Squibb stock steadies as investors weigh Opdivo growth and pending Karuna Therapeutics - Ad-hoc-news.de
BMS expands NVIDIA tie-up with Vera Rubin AI factory - The Pharma Letter
Bristol Myers Squibb stock holds steady as Eliquis and Opdivo underpin earnings outlook - Ad-hoc-news.de
Bristol Myers Squibb, NVIDIA build AI factory for drug discovery - MobiHealthNews
Alexandria Delivers R&D Hub for Bristol Myers Squibb at San Diego Megacampus - Connect CRE
Bristol Myers Squibb Expands AI Drug Discovery With NVIDIA Vera Rubin SuperPOD - AIM Media House
Bristol Myers Squibb expands Nvidia partnership to supercharge its AI drug factory - Crypto Briefing
Bristol Myers buys Nvidia's latest AI computing system for drug research - Reuters
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory - Pharmaceutical Executive
BMS, Nvidia aim for ‘most powerful AI factory in life sciences’ - Fierce Biotech
BMS again turns to NVIDIA to ramp up AI compute for drug discovery - FirstWord Pharma
Alexandria delivers 427,000 sq ft R&D facility for Bristol Myers - Investing.com
Bristol Myers Squibb to build the most powerful AI factory in life sciences with NVIDIA - Chain Drug Review
Bristol Myers boosts AI capacity with expanded use of Nvidia systems - Seeking Alpha
Bristol Myers Squibb expands AI infrastructure with NVIDIA By Investing.com - Investing.com Nigeria
Nvidia partners with Bristol-Myers Squibb to build AI supercomputer for drug discovery - Crypto Briefing
Bristol Myers Squibb expands AI infrastructure with NVIDIA - Investing.com
Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer - STAT
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA - marketscreener.com
Bristol Myers Squibb stock trades steady as oncology focus meets mixed revenue trends - Ad-hoc-news.de
Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis anchor earnings and pipeline focus - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as oncology and immunology portfolio underpins recent earni - Ad-hoc-news.de
Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma - simplywall.st
Bristol Myers Squibb stock trades steady as Revlimid erosion offsets Opdivo and Eliquis growth - ad-hoc-news.de
Bristol Myers Squibb Co (NYSE:BMY): A High Yield Dividend Stock Backed by Strong Profitability - ChartMill
Bristol Myers Squibb stock steadies as Opdivo and Eliquis underpin earnings power - ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo drive earnings and cash flow - Ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as cardiovascular and oncology portfolio supports earning - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as oncology and immunology portfolio underpins earnings - Ad-hoc-news.de
Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run? - simplywall.st
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb stock trades steady as oncology revenue and Celgene legacy shape valuation - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as Q1 2026 results highlight stronger Eliquis and Opdivo re - Ad-hoc-news.de
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline stays in focus for US in - Ad-hoc-news.de
Bristol-Myers Squibb stock holds steady as focus shifts to strategy - Ad-hoc-news.de
Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug - Law360
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada - Japan Wire by Kyodo News
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled - TradingKey
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada | Corporate - EQS News
Bristol-Myers Squibb Co (BMY) Shares Fall 4.0% -- What GF Score of 76 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.99% on Jul 14: Drivers Behind the Movement - TradingKey
Bristol Myers Squibb (BMY) Following FDA Acceptance Has An Undervalued Case - simplywall.st
Bristol-Myers Sues Aurobindo to Block Camzyos Heart Drug Copies - Bloomberg Law News
0.48%
0.05%
자본화:
|
볼륨(24시간):